文献速递功能神经外科

GPi与STN靶点脑深部电刺激治疗Meige综合征的疗效比较及结局预测因素:个体患者数据的系统评价

Efficacy comparison and outcome predictors of GPi- and STN-targeted deep brain stimulation for Meige syndrome: a systematic review of individual patient data.
PubMed 文献 · J Neurosurg · 2025-01-24

本系统评价汇总26项研究、233例Meige综合征患者的个体数据,评估脑深部电刺激(DBS)的疗效并比较苍白球内侧部(GPi)与丘脑底核(STN)靶点。末次随访时BFMDRS运动评分改善65.09%±26.65%、残疾评分改善53.48%±42.44%,两靶点疗效无显著差异;病程越长疗效越差,术前BFMDRS评分越高结局越好。

要点

  • 末次随访BFMDRS运动评分改善65.09%±26.65%,残疾评分改善53.48%±42.44%。
  • GPi与STN两靶点运动评分改善与应答风险差异均无统计学显著性。
  • 病程与疗效呈负相关、术前BFMDRS评分与结局呈正相关。

核心结论

  • DBS可显著改善Meige综合征患者的运动症状与残疾,GPi与STN靶点疗效相当。
  • DBS疗效随病程延长而减退,作者强调早期干预的重要性。

研究设计与样本

  • 系统检索PubMed、Embase和Web of Science数据库,收集Meige综合征接受DBS治疗的个体患者数据。
  • 共纳入26项研究、233例患者,采用合并meta分析,研究注册于PROSPERO数据库。

主要发现

  • 末次随访(平均27.10±33.64个月)BFMDRS-M评分改善65.09%±26.65%,BFMDRS-D评分改善53.48%±42.44%。
  • 末次随访时GPi组与STN组BFMDRS-M评分改善的平均差为-2.58%(95%CI -15.84%至10.69%;p=0.430),无显著差异。
  • 末次随访时GPi组与STN组应答风险差为-0.97%(95%CI -10.08%至8.15%;p=0.835),无显著差异,且在各随访时段(0至≤6、>6至≤12、>12至≤24、>24至≤36及>36个月)均无显著差异。
  • 多元回归分析显示病程与疗效呈负相关,术前BFMDRS评分与治疗结局呈正相关。

局限性

  • 分析存在显著发表偏倚(p=0.008,Egger检验)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to evaluate outcomes of deep brain stimulation (DBS) for Meige syndrome, compare the efficacy of globus pallidus internus (GPi) and subthalamic nucleus (STN) as targets, and identify potential outcome predictors. METHODS: The PubMed, Embase, and Web of Science databases were systematically searched to collect individual data from patients with Meige syndrome receiving DBS. Outcomes were assessed using the Burke-Fahn-Marsden Dystonia Rating Scale motor (BFMDRS-M) and disability (BFMDRS-D) scores. Data were analyzed using pooled meta-analysis. The study is registered in the PROSPERO database. RESULTS: The analysis included 233 patients from 26 studies, with significant publication bias (p = 0.008, Egger's test), but showed significant improvements in BFMDRS-M (65.09% ± 26.65%) and BFMDRS-D (53.48% ± 42.44%) scores at the final follow-up (mean duration 27.10 ± 33.64 months). No significant differences were observed in BFMDRS-M score improvement (mean difference -2.58%, 95% CI -15.84% to 10.69%; p = 0.430) or risk difference for response (-0.97%, 95% CI -10.08% to 8.15%; p = 0.835) between the GPi and STN target groups at the final follow-up across all follow-up periods (0 to ≤ 6, > 6 to ≤ 12, > 12 to ≤ 24, > 24 to ≤ 36, and > 36 months). Multiple regression analysis revealed a negative correlation between disease duration and treatment efficacy and a positive correlation between preoperative BFMDRS score and treatment outcome. CONCLUSIONS: DBS significantly improves motor symptoms and disability in patients with Meige syndrome, with GPi and STN targets providing comparable efficacy. The efficacy of DBS diminishes with longer disease duration, underscoring the importance of early intervention.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Xie H, Huang J, Diao Y, et al. Efficacy comparison and outcome predictors of GPi- and STN-targeted deep brain stimulation for Meige syndrome: a systematic review of individual patient data. J Neurosurg. 2025. PMID: 39854720. doi:10.3171/2024.9.JNS241263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。